‘Time to Double Down,’ Says Top Investor About Novo Nordisk Stock

Novo Nordisk (NVO) shares have shown a significant rebound, increasing by double digits following strong Q2 earnings that countered a prior 60% decline over the past year. The company reported an 18% rise in first-half sales and a 29% increase in operating profits, primarily driven by robust GLP-1 drug performance, including Ozempic sales up 35% and Wegovy up 67%, with notable international growth in Japan (+91%). This strong financial showing, coupled with strategic R&D in oral weight loss medicines and substantial manufacturing investments, underpins a bullish outlook from top investors like James Foord, who foresees a potential doubling of the stock, and a "Moderate Buy" consensus from Wall Street with over 40% upside.

Analysis

Despite a 60% share price decline over the past twelve months driven by regulatory and competitive pressures, Novo Nordisk (NVO) is showing strong signs of a fundamental turnaround. The company's Q2 2025 earnings report acted as a significant catalyst, revealing an 18% increase in sales and a 29% rise in operating profit for the first half of the year, which subsequently sparked a double-digit rally in the stock. This performance is overwhelmingly powered by its GLP-1 franchise, with Ozempic sales growing 35% and Wegovy sales surging 67%. The growth is not confined to North America, as evidenced by a 91% increase in GLP-1 drug sales in Japan during Q2. Forward-looking catalysts support a continued recovery, including multi-billion dollar investments to expand manufacturing capacity, promising R&D on an oral version of Wegovy that reportedly shows superior performance to a rival drug from Eli Lilly, and the potential for label expansion into new high-value indications like Alzheimer's. While Wall Street maintains a 'Moderate Buy' consensus with a $71.75 average price target implying over 40% upside, the sentiment is underpinned by confident individual analysts who see the recent pullback as a buying opportunity.

Key Decisions for Investors

• Investors could view the stock's significant prior correction as a potential long-term buying opportunity, given the robust Q2 financial results and accelerating sales growth in the core GLP-1 franchise.
• It is critical to monitor the progress of NVO's manufacturing expansion to assess its ability to meet exploding global demand and the clinical development of its oral Wegovy, which is a key potential differentiator against competitors like Eli Lilly.
• While the outlook appears strong, investors should note the 'Moderate Buy' consensus includes three 'Hold' ratings, suggesting a need to remain vigilant about the same regulatory and competitive risks that previously pressured the stock.